RT @ElizSMcKenna: An oldie but a goodie from 2014 in @CD_AACR ahead of today’s #ASCO23 plenary - the first report of AZD9291 (aka #osimerti…
An oldie but a goodie from 2014 in @CD_AACR ahead of today’s #ASCO23 plenary - the first report of AZD9291 (aka #osimertinib) https://t.co/RuI2nyE6Ks https://t.co/4sorA6rUN4
RT @CD_AACR: First published in 2014: AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Can…
RT @CD_AACR: First published in 2014: AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Can…
RT @CD_AACR: First published in 2014: AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Can…
First published in 2014: AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer https://t.co/BxgyIP4Jx7
Some examples of preclinical/translational papers in Cancer Discovery: https://t.co/BxgyIPmkoF https://t.co/t7b8vA3B0Z https://t.co/2fYRf9iFW5 *I-Mei (8/12)
RT @ElizSMcKenna: Sharing this classic @CD_AACR paper on osimertinib (then known as AZD9291) in honor of the ADAURA trial results presented…
Sharing this classic @CD_AACR paper on osimertinib (then known as AZD9291) in honor of the ADAURA trial results presented at #ESMO20 and published today: https://t.co/ZgPP7LbkBQ
Fascinating to learn about 3rd gen #EGFR TKI inhibitors for treatment of NSCLC in class today with @CharlesSawyers. Glad to be in an interdisciplinary grad program @WeillCornellGS where I can learn about cell signaling/cancer therapeutics and structural bi
RT @ElizSMcKenna: Exciting news! Read the original 2014 paper on this drug in @CD_AACR: https://t.co/tYWX6s5u2t https://t.co/gG8ljj87vP
RT @ElizSMcKenna: Exciting news! Read the original 2014 paper on this drug in @CD_AACR: https://t.co/tYWX6s5u2t
Exciting news! Read the original 2014 paper on this drug in @CD_AACR: https://t.co/tYWX6s5u2t
Brilliant MRC-PPU Alumni seminar today by Darren Cross of Astra Zeneca on development of AZD9291 to treat lung cancer http://t.co/g8x89rr5IN
Brilliant MRC-PPU Alumni seminar today by Darren Cross of Astra Zeneca on development of AZD9291 to treat lung cancer http://t.co/g8x89rr5IN
Pre-clinical work on AZD9291 http://t.co/wtgtGUYZ66
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in #lungcancer http://t.co/ndf6DYUJom
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in #lungcancer http://t.co/ndf6DYUJom
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in #lungcancer http://t.co/ndf6DYUJom
$AZN AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer http://t.co/7U6pCjIg1M